迪馬股份(600565.SH)近12個月累計涉及的訴訟、仲裁共計594筆
格隆匯9月18日丨迪馬股份(600565.SH)公佈,根據《上海證券交易所股票上市規則》有關規定,公司(包括控股子公司)近12個月新增累計涉及訴訟、仲裁事項進行了統計,累計涉及的訴訟、仲裁共計594筆,累計涉及的訴訟、仲裁金額合計86,207.61萬元,佔公司最近一期經審計歸屬於上市公司股東的淨資產金額861,793.57萬元的10.003%,其中累計未結訴訟、仲裁案件金額合計54,769.29萬元,累計已結訴訟、仲裁案件金額為31,438.32萬元;累計主動訴訟、仲裁金額合計為30,493.62萬元,累計被動訴訟、仲裁金額合計為55,713.99萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.